{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:16:51Z","timestamp":1778883411983,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.08.086","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T07:33:55Z","timestamp":1631518435000},"page":"6025-6036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hexavalent vaccines: What can we learn from head-to-head studies?"],"prefix":"10.1016","volume":"39","author":[{"given":"Markus","family":"Knuf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garcia-Corbeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-065X","authenticated-orcid":false,"given":"Elisa","family":"Turriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-3795","authenticated-orcid":false,"given":"Piyali","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-3468","authenticated-orcid":false,"given":"Winnie","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Berlaimont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2021.08.086_b0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14760584.2018.1419070","article-title":"Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer","volume":"17","author":"Dolhain","year":"2018","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2021.08.086_b0010","unstructured":"European Medicines Agency (EMA). Hexavac [diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted]. Withdrawal of marketing authorisation in the European Union, https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-hexavac-withdrawal-marketing-authorisation-european-union_en.pdf ; 2012 [accessed 05 October 2020]."},{"key":"10.1016\/j.vaccine.2021.08.086_b0015","unstructured":"European Medicines Agency (EMA). Infanrix Hexa EMA summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000296\/WC500032505.pdf ; 2020 [accessed 05 August 2020]."},{"key":"10.1016\/j.vaccine.2021.08.086_b0020","unstructured":"European Medicines Agency (EMA). Hexyon EMA summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/002796\/WC500145758.pdf ; 2020 [accessed 05 August 2020]."},{"key":"10.1016\/j.vaccine.2021.08.086_b0025","unstructured":"European Medicines Agency (EMA). Vaxelis EMA summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003982\/WC500202435.pdf ; 2020 [accessed 05 August 2020]."},{"key":"10.1016\/j.vaccine.2021.08.086_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14760584.2021.1892493","article-title":"Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines","volume":"20","author":"Mukherjee","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.086_b0035","unstructured":"Pharma Intelligence. Trialtrove: gold standard clinical trials intelligence, https:\/\/pharmaintelligence.informa.com\/products-and-services\/data-and-analysis\/trialtrove; 2021 [accessed 11 February 2021]."},{"issue":"45","key":"10.1016\/j.vaccine.2021.08.086_b0040","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2012.07.040","article-title":"A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children","volume":"30","author":"Aquino","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.086_b0045","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.086_b0050","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7560.1000128","article-title":"Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2\u20134-6 months of Age in Peru","volume":"03","author":"Lanata","year":"2012","journal-title":"J Vaccines Vaccin."},{"key":"10.1016\/j.vaccine.2021.08.086_b0055","doi-asserted-by":"crossref","unstructured":"L\u00f3pez P, Arguedas Mohs A, Abdelnour V\u00e1squez A, Consuelo-Miranda M, Feroldi E, Noriega F, et al. A randomized controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Infect Dis J. 2017;36:e272-e82. http:\/\/dx.doi.org\/10.1097\/inf.0000000000001682.","DOI":"10.1097\/INF.0000000000001682"},{"key":"10.1016\/j.vaccine.2021.08.086_b0060","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/INF.0000000000002109","article-title":"Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic","volume":"37","author":"Prymula","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.086_b0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21645515.2018.1546524","article-title":"Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration","volume":"15","author":"Madhi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.086_b0070","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/21645515.2018.1426418","article-title":"Persistence of hepatitis B immune memory until 9\u201310 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP\u223cT vaccination at 2, 4 and 6 months","volume":"14","author":"Kosalaraksa","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.086_b0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/INF.0000000000001358","article-title":"A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.08.086_b0080","doi-asserted-by":"crossref","unstructured":"Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017b;36:209-15. http:\/\/dx.doi.org\/10.1097\/inf.0000000000001406.","DOI":"10.1097\/INF.0000000000001406"},{"issue":"33","key":"10.1016\/j.vaccine.2021.08.086_b0085","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.086_b0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/21645515.2019.1673119","article-title":"Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/21645515.2020.1756668","article-title":"Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis\u2122) in premature infants","volume":"17","author":"Wilck","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.086_b0100","unstructured":"World Health Organization. Annex 4 - Recommendations to assure the quality, safety and efficacy of diphtheria vaccines (adsorbed). Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927, https:\/\/www.who.int\/biologicals\/vaccines\/Diphtheria_Recommendations_TRS_980_Annex_4.pdf?ua=1 ; 2014 [accessed 05 October 2020]."},{"key":"10.1016\/j.vaccine.2021.08.086_b0105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/ciz205","article-title":"How important is the type of acellular pertussis vaccine?","volume":"70","author":"Harriman","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.086_b0110","doi-asserted-by":"crossref","first-page":"A345","DOI":"10.1016\/j.jval.2013.08.135","article-title":"Estimating the cost impact of switching from a vial to a pre-filled syringe mode of administration for the DTaA-IPV-Hib \u20185-In-1\u2019 vaccine in infants","volume":"16","author":"Kumar","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.086_b0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.vaccine.2008.11.045","article-title":"Simplifying paediatric immunization with a fully liquid DTP\u2013HepB\u2013Hib combination vaccine: evidence from a comparative time-motion study in India","volume":"27","author":"Wiedenmayer","year":"2009","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2021.08.086_b0120","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2015.06.030","article-title":"Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study","volume":"33","author":"De Coster","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.086_b0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14760584.2020.1800458","article-title":"Safety profile of Infanrix hexa \u2013 17 years of GSK\u2019s passive post-marketing surveillance","volume":"19","author":"Puente G\u00f3mez","year":"2020","journal-title":"Expert Rev Vacc"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/14760584.6.1.47","article-title":"Acellular pertussis vaccines and the role of pertactin and fimbriae","volume":"6","author":"Poolman","year":"2007","journal-title":"Expert Rev Vacc"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.086_b0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.88.2.345","article-title":"Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells","volume":"88","author":"Leininger","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.086_b0140","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/377283","article-title":"Crucial role of antibodies to pertactin in Bordetella pertussis immunity","volume":"188","author":"Hellwig","year":"2003","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/21645515.2020.1764826","article-title":"Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV\/Hib vaccine","volume":"17","author":"Bayliss","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/hv.26269","article-title":"Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine; Infanrix\u2122 hexa","volume":"10","author":"Baldo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"46","key":"10.1016\/j.vaccine.2021.08.086_b0155","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1016\/j.vaccine.2017.09.077","article-title":"Impact of Haemophilus influenzae type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy","volume":"35","author":"Martinelli","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.086_b0160","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00431-012-1791-8","article-title":"Hospitalizations for pertussis in Italy, 1999\u20132009: analysis of the hospital discharge database","volume":"171","author":"Gabutti","year":"2012","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2021.08.086_b0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijid.2019.10.027","article-title":"Impact of pertussis on the Italian population: Analysis of hospital discharge records in the period 2001\u20132014","volume":"91","author":"Brosio","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.086_b0170","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.vaccine.2019.11.069","article-title":"Dose-dependent effectiveness of acellular pertussis vaccine in infants: a population-based case-control study","volume":"38","author":"Mack","year":"2020","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.086_b0175","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1586\/erv.09.88","article-title":"Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience","volume":"8","author":"Hallander","year":"2009","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2021.08.086_b0180","unstructured":"Aronsson B, K\u00e4llberg H, Bystr\u00f6m E, Storsaeter J, Roth A, Andersson S. Vaccine effectiveness of acellular pertussis vaccine estimated by the screening method, Swedish preschool children, 2007-2018 [abstract]. In Proceedings of the 38th Annual Meeting of The European Society for Paediatric Infectious Diseases (ESPID); 2020 October 26-29; Virtual Meeting; Abstract O071."},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.086_b0185","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14760584.2020.1825948","article-title":"Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication","volume":"19","author":"Slack","year":"2020","journal-title":"Expert Rev Vac"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.086_b0190","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/315870","article-title":"Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration","volume":"182","author":"Fernandez","year":"2000","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2021.08.086_b0195","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.vaccine.2008.03.001","article-title":"Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure","volume":"26","author":"Kalies","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.086_b0200","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1473-3099(18)30166-X","article-title":"Effectiveness of the DTPa-HBV-IPV\/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003\u201316): a case-control study","volume":"18","author":"Monge","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.086_b0205","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14760584.2017.1383157","article-title":"A review of Haemophilus influenzae disease in Europe from 2000\u20132014: challenges, successes and the contribution of hexavalent combination vaccines","volume":"16","author":"Wang","year":"2017","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2021.08.086_b0210","unstructured":"Robert Koch-Institut. Epidemiologisches Bulletin 26 \/ 2020. 2020. http:\/\/dx.doi.org\/10.25646\/7072."},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.086_b0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00431-002-1079-5","article-title":"Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV\/Hib vaccine compared to separate concomitant injections of DTPa-IPV\/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule","volume":"161","author":"Avdicov\u00e1","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2021.08.086_b0220","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/INF.0000000000002954","article-title":"Persistence of hepatitis B immune memory until 6 years of age following hexavalent DTaP-IPV-HB-PRP\u223cT vaccination in a 3-, 5- and 11- to 12-month schedule and response to a subsequent hepatitis B challenge vaccination","volume":"40","author":"Virta","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0225","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21645515.2018.1509658","article-title":"Long-term antibody persistence against hepatitis B in adolescents 14\u201315-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV\/Hib vaccine in infancy","volume":"15","author":"Schwarz","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.086_b0230","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/21645515.2016.1202388","article-title":"Lasting immune memory against hepatitis B in 12\u201313-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV\/Hib vaccine in infancy","volume":"12","author":"Behre","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.086_b0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4161\/hv.6.2.10117","article-title":"Immunological persistence in 4\u20136 and 7\u20139 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV\/Hib","volume":"6","author":"Zinke","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2021.08.086_b0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2334-10-9","article-title":"Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV\/Hib in the first and 2nd year of life","volume":"10","author":"Steiner","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.086_b0245","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.4161\/hv.28480","article-title":"Immune memory to hepatitis B persists in children aged 7\u20138 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV\/Hib (Infanrix\u2122 hexa) vaccine","volume":"10","author":"Van Der Meeren","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"10.1016\/j.vaccine.2021.08.086_b0250","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.vaccine.2014.06.070","article-title":"Lasting immune memory against hepatitis B following challenge 10\u201311 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV\/Hib or monovalent hepatitis B vaccine at 3, 5 and 11\u201312 months of age","volume":"33","author":"Avdicova","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.086_b0255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2893.2010.01312.x","article-title":"Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region","volume":"18","author":"Poovorawan","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vaccine.2021.08.086_b0260","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jvh.13125","article-title":"Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults","volume":"26","author":"Van Damme","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vaccine.2021.08.086_b0265","unstructured":"European Medicines Agency (EMA). Vaccine schedules in all countries of the European Union, https:\/\/vaccine-schedule.ecdc.europa.eu\/ ; 2021 [accessed 16 February 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.086_b0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40272-016-0208-y","article-title":"DTaP5-HB-IPV-Hib vaccine (Vaxelis\u00ae): a review of its use in primary and booster vaccination","volume":"19","author":"Syed","year":"2017","journal-title":"Paediatr Drugs"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:01:42Z","timestamp":1759402902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21011464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":54,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21011464"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hexavalent vaccines: What can we learn from head-to-head studies?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}